Adma Biologics reported $52.44M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Adma Biologics USD 52.44M 2.15M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Novavax USD 20.94M 100.32M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Takeda JPY 205.32B 3.9B Sep/2026